Key Points
- Indivior CAO Woodrow Anderson purchased 1,500 shares at $35.69 each, investing $53,535 and increasing his direct ownership by 5.74% to 27,638 shares.
- Indivior shares opened at $35.30 after falling 1.5%; the company has a $4.17 billion market capitalization and recently reported $343 million in quarterly revenue and $5.75 EPS.
- Analysts maintain a broadly positive outlook, with a consensus “Moderate Buy” rating and a $45.17 price target, while institutional investors own 60.33% of the stock.
Indivior PLC (NASDAQ:INDV - Get Free Report) CAO Woodrow Anderson bought 1,500 shares of the company's stock in a transaction dated Thursday, August 27th. The shares were acquired at an average price of $35.69 per share, for a total transaction of $53,535.00. Following the completion of the transaction, the chief accounting officer directly owned 27,638 shares in the company, valued at approximately $986,400.22. This trade represents a 5.74% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.
Indivior Trading Down 1.5%
NASDAQ INDV opened at $35.30 on Friday. The stock has a market capitalization of $4.17 billion, a price-to-earnings ratio of 12.65 and a beta of 0.86. Indivior PLC has a twelve month low of $22.22 and a twelve month high of $42.81. The stock has a 50-day moving average of $39.40 and a 200 day moving average of $36.00.
Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%.The company had revenue of $343.00 million for the quarter. Equities analysts predict that Indivior PLC will post 3.66 EPS for the current fiscal year.
Institutional Trading of Indivior
Large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. raised its holdings in Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company's stock valued at $79,757,000 after acquiring an additional 1,299,425 shares during the last quarter. Fuller & Thaler Asset Management Inc. boosted its holdings in shares of Indivior by 101.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company's stock worth $228,611,000 after purchasing an additional 3,201,639 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Indivior by 57.9% in the fourth quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company's stock valued at $196,403,000 after purchasing an additional 2,008,078 shares in the last quarter. California State Teachers Retirement System acquired a new stake in shares of Indivior in the second quarter valued at approximately $201,163,000. Finally, State Street Corp increased its holdings in shares of Indivior by 65.5% in the fourth quarter. State Street Corp now owns 4,659,281 shares of the company's stock valued at $167,175,000 after purchasing an additional 1,844,532 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms have issued reports on INDV. Craig Hallum reaffirmed a "buy" rating and set a $53.00 price objective on shares of Indivior in a report on Tuesday, August 4th. Barclays reduced their price target on shares of Indivior from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Wednesday, August 5th. Zacks Research lowered shares of Indivior from a "strong-buy" rating to a "hold" rating in a research note on Monday, June 29th. Finally, Weiss Ratings cut Indivior from a "buy (b-)" rating to a "hold (c+)" rating in a report on Friday, August 21st. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Indivior currently has a consensus rating of "Moderate Buy" and a consensus price target of $45.17.
Check Out Our Latest Report on Indivior
About Indivior
(
Get Free Report)
Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company's portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.
Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
